B7-H3 Inhibitors

Chrysin inhibits B7-H3 indirectly by modulating the NF-κB signaling pathway. Acting as a potent inhibitor of IκB kinase, Chrysin hinders the phosphorylation and subsequent degradation of IκBα, preventing NF-κB translocation to the nucleus. This disruption dampens the transcriptional activation of target genes, including those implicated in B7-H3 expression, thus indirectly downregulating B7-H3.

SB203580 serves as an indirect inhibitor of B7-H3 by influencing the p38 MAPK pathway. This chemical inhibits p38α, a key kinase in the pathway, disrupting downstream signaling events. Importantly, p38 MAPK is involved in the post-transcriptional regulation of B7-H3, and SB203580's action on this pathway results in reduced translation and stability of B7-H3 mRNA. Consequently, B7-H3 protein levels decrease, contributing to its inhibition.

Rapamycin acts indirectly on B7-H3 by inhibiting the mTORC1 signaling pathway. mTORC1 is known to regulate B7-H3 expression through the control of HIF-1α stability. By inhibiting mTORC1, Rapamycin impedes HIF-1α accumulation, thereby downregulating B7-H3 transcription. This indirect modulation results in reduced B7-H3 protein levels and activity.

SP600125 acts as an indirect inhibitor of B7-H3 by targeting the JNK signaling pathway. By inhibiting JNK, SP600125 disrupts the downstream signaling cascades, including the AP-1 transcription factor. AP-1 is implicated in the transcriptional activation of B7-H3. Consequently, SP600125-mediated inhibition of JNK leads to decreased AP-1 activity and reduced expression of B7-H3, contributing to its indirect inhibition.

LY294002 functions as an indirect inhibitor of B7-H3 through the inhibition of the PI3K/Akt signaling pathway. Given the role of Akt in promoting B7-H3 expression, LY294002's inhibition of Akt phosphorylation leads to decreased B7-H3 expression. This indirect modulation occurs at the transcriptional level, with reduced Akt activity resulting in diminished activation of transcription factors involved in B7-H3 gene expression.

Also called JSH-23, this compound acts as an indirect inhibitor of B7-H3 by targeting the NF-κB signaling pathway. By inhibiting the nuclear translocation of NF-κB, JSH-23 prevents its binding to the B7-H3 promoter region. This interference disrupts the transcriptional activation of B7-H3, leading to reduced mRNA levels and subsequently lower B7-H3 protein expression.

Wortmannin serves as an indirect inhibitor of B7-H3 by targeting the PI3K signaling pathway. Through the irreversible inhibition of PI3K, Wortmannin disrupts the downstream Akt/mTOR pathway, known to regulate B7-H3 expression. The resulting inhibition of Akt activity hinders the transcriptional activation of B7-H3, leading to decreased mRNA levels and subsequent reduction in B7-H3 protein expression.

Trametinib acts as an indirect inhibitor of B7-H3 by targeting the MEK/ERK signaling pathway. Inhibiting MEK, a kinase upstream of ERK, Trametinib disrupts the phosphorylation cascade that regulates B7-H3 expression. Specifically, this compound interferes with the activation of transcription factors involved in B7-H3 gene expression, resulting in decreased mRNA levels and subsequent inhibition of B7-H3 protein expression.

BAY 11-7082 serves as an indirect inhibitor of B7-H3 by targeting the NF-κB signaling pathway. Through the inhibition of IκBα phosphorylation and subsequent NF-κB activation, BAY 11-7082 prevents the transcriptional activation of B7-H3. This interference leads to decreased mRNA levels and subsequent reduction in B7-H3 protein expression, contributing to its indirect inhibition.

PD98059 acts as an indirect inhibitor of B7-H3 by targeting the MEK/ERK signaling pathway. By inhibiting MEK, PD98059 disrupts the phosphorylation cascade that regulates B7-H3 expression. This compound interferes with the activation of transcription factors involved in B7-H3 gene expression, resulting in decreased mRNA levels and subsequent inhibition of B7-H3 protein expression.